EWTX (STOCKS)
Edgewise Therapeutics, Inc. Common Stock
$33.840000
+1.020000 (+3.11%)
Prev close: $32.820000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Kevin Koch
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $3,627.91M
- Employees
- 136
- P/E (TTM)
- -20.73
- P/B (TTM)
- 6.68
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $191.41M |
| Research and Development | $151.39M |
| Other Operating Expenses | $40.02M |
| Operating Income/Loss | -$191.41M |
| Income/Loss From Continuing Operations After Tax | -$167.80M |
| Income/Loss From Continuing Operations Before Tax | -$167.80M |
| Income Tax Expense/Benefit | $4.00K |
| Net Income/Loss | -$167.80M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$167.80M |
| Net Income/Loss Available To Common Stockholders, Basic | -$167.80M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.63 |
| Diluted Earnings Per Share | -$1.63 |
| Basic Average Shares | 102,930,744 |
| Diluted Average Shares | 102,930,744 |
| Assets | $552.60M |
| Current Assets | $543.39M |
| Noncurrent Assets | $9.22M |
| Fixed Assets | $7.83M |
| Other Non-current Assets | $1.39M |
| Liabilities | $30.35M |
| Current Liabilities | $27.37M |
| Accounts Payable | $6.01M |
| Wages | $12.43M |
| Other Current Liabilities | $8.93M |
| Noncurrent Liabilities | $2.98M |
| Equity | $522.26M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $522.26M |
| Liabilities And Equity | $552.60M |
| Net Cash Flow From Operating Activities | -$143.82M |
| Net Cash Flow From Operating Activities, Continuing | -$143.82M |
| Net Cash Flow From Investing Activities | -$32.79M |
| Net Cash Flow From Investing Activities, Continuing | -$32.79M |
| Net Cash Flow From Financing Activities | $196.09M |
| Net Cash Flow From Financing Activities, Continuing | $196.09M |
| Net Cash Flow | $19.48M |
| Net Cash Flow, Continuing | $19.48M |
| Comprehensive Income/Loss | -$167.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$167.54M |
| Other Comprehensive Income/Loss | $257.00K |